InvestorsHub Logo
Followers 105
Posts 16576
Boards Moderated 0
Alias Born 06/24/2014

Re: None

Wednesday, 04/26/2023 5:33:44 PM

Wednesday, April 26, 2023 5:33:44 PM

Post# of 227
N excella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMMX News